Screener
Stoke Therapeutics, Inc. STOK MECP2 — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Zorevunersen(1) | 19,854 | 17,674 |
| ADOA(1) | 1,859 | 1,201 |
| SYNGAP1(1) | 745 | 342 |
| MECP2(1) | — | 147 |
| Other external program costs | 3,178 | 1,829 |
| Payroll and other personnel costs - R&D (2) | 16,118 | 11,012 |
| Payroll and other personnel costs - SG&A (2) | 11,057 | 8,929 |
| Other non-program costs - R&D (3) | 1,680 | 1,407 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s MECP2 — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported MECP2 — operating expenses of $0 in Q1 2026.
- How has Stoke Therapeutics, Inc.'s MECP2 — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s MECP2 — operating expenses increased by 100.0% year-over-year, from -$147K to $0.
- What is the long-term trend for Stoke Therapeutics, Inc.'s MECP2 — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s MECP2 — operating expenses has grown at a -80.7% compound annual growth rate (CAGR), from -$991K to $37K.
- What does MECP2 — operating expenses mean?
- This metric represents the total costs directly attributable to the research, development, and operational activities associated with the MECP2 therapeutic program. It captures the investment required to advance this specific pipeline asset through preclinical and clinical stages, including personnel, laboratory, and external trial costs. Monitoring these expenses provides insight into the capital intensity and resource allocation strategy for this specific drug development candidate.
Ask your AI about Stoke Therapeutics, Inc.'s mecp2 — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude